A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer

British Journal of Cancer

Volumn 100, Issue 1, 2009, Pages 37-43

  Michael, M ^a   Price, T ^b,c   Ngan, S Y ^a   Ganju, V ^d   Strickland, A H ^e   Muller, A ^f   Khamly, K ^a   Milner, A D ^a   Dilulio, J ^a   Matera, A ^a   Zalcberg, J R ^a   Leong, T ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c LYELL MCEWIN HOSPITAL   (Australia)

^d FRANKSTON HOSPITAL   (Australia)

^e MONASH MEDICAL CENTRE   (Australia)

^f FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Capecitabine; Chemoradiotherapy; Gemcitabine; Pancreatic cancer

Indexed keywords

CAPECITABINE; GEMCITABINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; HYPOKALEMIA; MALE; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 58149231133     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604827     Document Type: Article

References (39)

1. Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA (2004) Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59: 454-459
2. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208-2212
3. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA (2003) Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34: 107-116
4. Brade A, Brierley J, Oza A, Gallinger S, Cummings B, Maclean M, Pond GR, Hedley D, Wong S, Townsley C, Brezden-Masley C, Moore M (2007) Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys 67: 1027-1036
5. Cengiz M, Zorlu F, Yalcin S, Gurkaynak M, Atahan IL, Gullu IH (2007) Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Med Oncol 24: 239-243
6. Cohen SJ, Dobelbower Jr R, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62: 1345-1350
7. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA (2006) Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24: 1145-1151
8. Cunningham D, Chau I, Stocken C, Davies C, Dunn J, Valle J, Smith D, Steward W, Harper P, Neoptolemos J (2005) Phase III randomised comparison of gemcitabine (GEM) vs gemcitabine plus capecitabine (GEM-CAP) in patients with advanced ponacreatic cancer. Eur J Cancer 18(Supplement 7): PS11 (Abstract)
9. Czito B, Willett C, Hurwitz H, Morse H, Tyler D, Fernando N, Mantyh C, Blobe G, Honeycutt W, Bendell J (2006) Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. ASCO Gastrointestinal Cancers Symposium: 116 (Abstract)
10. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H (1993) Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32: 333-338
11. Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S, Kuten A (2002) Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81: 138-143
12. Fields MT, Eisbruch A, Normolle D, Orfali A, Davis MA, Pu AT, Lawrence TS (2000) Radiosensitization produced in vivo by once- vs twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 47: 785-791
13. Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, Shapiro J, Davies T, Reece W, Harvey J, Spry N (2007) Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 97: 464-471
14. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25: 326-331
15. Kim R, Saif MW (2007) Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP 8: 279-288
16. Kindler H, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod H, Mulcahy M, Schilsky R, Goldberg R, B C.a.L.G (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) vs gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB. J Clin Oncol 25: 4508 (Abstract)
17. Krempien R, Munter M, Timke C, Friess H, Hartung G, Herfarth K, Abdollahi A, Buchler M, Huber P, Debus J (2007) Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: A prospective phase II trial [PARC-Study ISRCTN56652283]. J Clin Oncol 25: 4573 (Abstract)
18. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro- 2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34: 867-872
19. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL (2006) Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 24: 1720-1728
20. Loehrer P, Powell M, Cardenes H, Wagner L, Brell J, Ramanathan R, Crane C, Alberts S, Benson A, Group E.C.O (2008) A randomized phase III study of gemcitabine in combination with radiation therapy vs gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 26(May 20 suppl), Abstract 4056
21. Martenson JA, Vigliotti AP, Pitot HC, Geeraerts LH, Sargent DJ, Haddock MG, Ghosh C, Keppen MD, Fitch TR, Goldberg RM (2003) A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 55: 1305-1310
22. Martin C, Lund B, Anderson H, Thatcher N (1996) Gemcitabine: onceweekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 7: 351-357
23. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas Jr HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48: 1705-1710
24. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966
25. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Haraguchi N, Inoue H, Murayama S, Mori M (2006) Differential gene expression profiles of radioresistant pancreatic cancer cell lines established by fractionated irradiation. Int J Oncol 28: 705-713
26. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H (2004) Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 91: 673-677
27. Pipas JM, Barth Jr RJ, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N, Meyer LP, Marshall JF, Cole BF, Colacchio TA (2005) Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12: 995-1004
28. Pipas JM, Mitchell SE, Barth Jr RJ, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP (2001) Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50: 1317-1322
29. Poggi MM, Kroog GS, Russo A, Muir C, Cook J, Smith J, Mitchell JB, Herscher LL (2002) Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54: 670-676
30. Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB (2007) Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 13: 247-256
31. Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23: 8679-8687
32. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H (1999) X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5: 2948-2953
33. Schneider BJ, Ben-Josef E, McGinn CJ, Chang AE, Colletti LM, Normolle DP, Hejna GF, Lawrence TS, Zalupski MM (2005) Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63: 1325-1330
34. Small W, Mulcahy M, Benson A, Gold S, Rademaker F, Bentrem D, Talamonti M (2008) A phase II trial of weekly gemcitabine and bevacizumab in combination with abdominal radiation therapy in patients with localized pancreatic cancer. ASCO Gastrointestinal Cancers Symposium: 131 (Abstract)
35. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, Ghaneh P (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96: 1183-1190
36. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson III AB (2000) Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18: 3384-3389
37. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J (2007) The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 18(Suppl 7): vii1-vii10
38. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7: 2246-2253
39. Yamazaki H, Nishiyama K, Koizumi M (2004) [Concurrent chemoradiotherapy using full-dose gemcitabine for patients with unresectable pancreatic cancer]. Nippon Igaku Hoshasen Gakkai Zasshi 64: 216-219